Cargando…

Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout

OBJECTIVE: Lesinurad (LESU) is a selective urate reabsorption inhibitor approved at 200 mg daily for use with a xanthine oxidase inhibitor (XOI) to treat hyperuricaemia in gout patients failing to achieve target serum urate on XOI. The aim of the study was to investigate the long-term safety of LESU...

Descripción completa

Detalles Bibliográficos
Autores principales:	Terkeltaub, Robert, Saag, Kenneth G, Goldfarb, David S, Baumgartner, Scott, Schechter, Bruce M, Valiyil, Ritu, Jalal, Diana, Pillinger, Michael, White, William B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293483/ https://www.ncbi.nlm.nih.gov/pubmed/30124941 http://dx.doi.org/10.1093/rheumatology/key245

Ejemplares similares

Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial
por: Dalbeth, Nicola, et al.
Publicado: (2017)

In Vitro and In Vivo Interaction Studies Between Lesinurad, a Selective Urate Reabsorption Inhibitor, and Major Liver or Kidney Transporters
por: Shen, Zancong, et al.
Publicado: (2016)

Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study
por: Dalbeth, Nicola, et al.
Publicado: (2019)

Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney
por: Miner, Jeffrey, et al.
Publicado: (2016)

Efficacy and safety of lesinurad for the treatment of hyperuricemia in gout
por: Pérez-Ruiz, Fernando, et al.
Publicado: (2019)

Erratum to: Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney
por: Miner, Jeffrey N., et al.
Publicado: (2016)

Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males
por: Shen, Zancong, et al.
Publicado: (2015)

Variation in serum urate levels in the absence of gout and urate lowering therapy
por: Shaffer, Andrew, et al.
Publicado: (2021)

The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout
por: Baumgartner, Scott, et al.
Publicado: (2018)

A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout
por: Hosoya, Tatsuo, et al.
Publicado: (2020)

Patient considerations in the management of gout and role of combination treatment with lesinurad
por: Claus, Liza W, et al.
Publicado: (2018)

Lesinurad: A significant advancement or just another addition to existing therapies of gout?
por: Gupta, Ajay, et al.
Publicado: (2016)

Guideline development for the management of gout: role of combination therapy with a focus on lesinurad
por: Jones, Graeme, et al.
Publicado: (2017)

A clinical pharmacology study of the novel, selective urate reabsorption inhibitor dotinurad in outpatients
por: Hosoya, Tatsuo, et al.
Publicado: (2020)

Effects of mild and moderate renal dysfunction on pharmacokinetics, pharmacodynamics, and safety of dotinurad: a novel selective urate reabsorption inhibitor
por: Fukase, Hiroyuki, et al.
Publicado: (2019)

Guideline development for the management of gout: role of combination therapy with a focus on lesinurad [Corrigendum]
Publicado: (2017)

Reassessing the Safety Profile of Lesinurad in Combination with Xanthine Oxidase Inhibitor Therapy
por: Perez-Ruiz, Fernando, et al.
Publicado: (2019)

Sex differences in gout characteristics: tailoring care for women and men
por: Harrold, Leslie R., et al.
Publicado: (2017)

Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia
por: Kuriyama, Satoru
Publicado: (2019)

Urate transporter inhibitor lesinurad is a selective peroxisome proliferator-activated receptor gamma modulator (sPPARγM) in vitro
por: Heitel, Pascal, et al.
Publicado: (2018)

Urate in fingernail represents the deposition of urate burden in gout patients
por: Chen, Haibing, et al.
Publicado: (2020)

Dotinurad: a clinical pharmacokinetic study of a novel, selective urate reabsorption inhibitor in subjects with hepatic impairment
por: Kumagai, Yuji, et al.
Publicado: (2019)

Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study
por: Hosoya, Tatsuo, et al.
Publicado: (2019)

Gout. Novel therapies for treatment of gout and hyperuricemia
por: Terkeltaub, Robert
Publicado: (2009)

The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor
por: Okui, Daisuke, et al.
Publicado: (2019)

SLC2A9 (GLUT9) mediates urate reabsorption in the mouse kidney
por: Auberson, Muriel, et al.
Publicado: (2018)

Decrease in Serum Urate Level Is Associated With Loss of Visceral Fat in Male Gout Patients
por: Ran, Zijing, et al.
Publicado: (2021)

Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study
por: Hosoya, Tatsuo, et al.
Publicado: (2019)

Xanthine oxidase inhibitor urate-lowering therapy titration to target decreases serum free fatty acids in gout and suppresses lipolysis by adipocytes
por: Guma, Monica, et al.
Publicado: (2022)

The inflammatory process of gout and its treatment
por: Cronstein, Bruce N, et al.
Publicado: (2006)

Lesinurad: what the nephrologist should know
por: Sanchez-Niño, Maria Dolores, et al.
Publicado: (2017)

Adherence with urate-lowering therapies for the treatment of gout
por: Harrold, Leslie R, et al.
Publicado: (2009)

Systemic Urate Deposition: An Unrecognized Complication of Gout?
por: Khanna, Puja, et al.
Publicado: (2020)

Urate‐lowering therapy for patients with gout on hemodialysis
por: Alkilany, Reem, et al.
Publicado: (2022)

Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study)
por: Bardin, Thomas, et al.
Publicado: (2017)

Comparative study of a novel selective urate reabsorption inhibitor “dotinurad” among patient groups with different stages of renal dysfunction
por: Takahashi, Toshinari, et al.
Publicado: (2021)

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
por: Becker, Michael A, et al.
Publicado: (2010)

The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age
por: Jackson, Robert L, et al.
Publicado: (2012)

Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial
por: Saag, Kenneth G., et al.
Publicado: (2022)

Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol
por: Perez-Ruiz, Fernando, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_mevega8ncvm4qf8k3lftcm1nnt